Colorectal Cancer Prevention, Early Detection, and Treatment Act

H.R. 733 & S. 362: Pancreatic Cancer Research & Education Act H.R. 2239: Functional Gastrointestinal & Motility Disorders (FGIMD) Research Enhancement Act H.R. 2108 & S. 1173: Ambulatory Surgical Center Quality & Access Act H.R. 2195 & S. 1203: Medicare Home Infusion Therapy Coverage H.R. 3839: Drug shortage legislation including: The Drug Shortage Prevention Act H.R. 2245/S.296: The Preserving Access to Life Saving Medications Act H.R. 3381/S. 1809: Viral Hepatitis Testing Act H.R. 3198: Supporting Colorectal Examination & Education Now (SCREEN) Act H.R. 912/S. 494: Colorectal Cancer Prevention, Early Detection, and Treatment Act H.R. 3211/S. 1865: Patient Access to Medical Innovation Act: Humanitarian Device Reform Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.

Client expense: $420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S. 1064, the Sun Act; S 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S.3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, Amendment relating to S.1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Issues relating to global health including S. 2515, the Clean Cookstoves Support Act of 2012.

Client expense: $590,000 · Firm income: Not reported

H.R .733 & S. 362: Pancreatic Cancer Research & Education Act H.R. 2239: Functional Gastrointestinal & Motility Disorders (FGIMD)Research Enhancement Act H.R. 2108 & S. 1173: Ambulatory Surgical Center Quality & Access Act H.R. 2195 & S. 1203: Medicare Home Infusion Therapy Coverage H.R.3839: Drug shortage legislation including: The Drug Shortage Prevention Act H.R. 2245/S. 296: The Preserving Access to Life Saving Medications Act H.R. 3381/S. 1809: Viral Hepatitis Testing Act H.R. 3198: Supporting Colorectal Examination & Education Now (SCREEN) Act H.R. 912/S. 494: Colorectal Cancer Prevention, Early Detection, and Treatment Act H.R. 3211/S. 1865: Patient Access to Medical Innovation Act: Humanitarian Device Reform Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S. 1064, the Sun Act; S 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, and issues relating to the ongoing national shortage of cancer drugs, Amendment relating to S.1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.

Client expense: $750,000 · Firm income: Not reported

Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; HR 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; HR 2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, and issues relating to the ongoing national shortage of cancer drugs.

Client expense: $360,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 733/S. 362: Pancreatic Cancer Research & Education Act H.R. 2239: Functional Gastrointestinal & Motility Disorders (FGIMD) Research Enhancement Act H.R. 2108/S. 1173: Ambulatory Surgical Center Quality & Access Act H.R. 2195/S. 1203: Medicare Home Infusion Therapy Coverage H.R.3839: Drug shortage legislation including: The Drug Shortage Prevention Act H.R. 2245/S. 296: The Preserving Access to Life Saving Medications Act H.R. 3381/S. 1809: Viral Hepatitis Testing Act H.R. 3198: Supporting Colorectal Examination & Education Now (SCREEN) Act H.R. 912/S. 494: Colorectal Cancer Prevention, Early Detection, and Treatment Act H.R. 3211/S. 1865: Patient Access to Medical Innovation Act: Humanitarian Device Reform Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S 494 and HR 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; HR 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; HR 1217, Repeal Prevention and Public Health Fund; HR 1740 and HR 5560, the Quality Cancer Care for Life Act of 2010; HR 2941 and S 3493; HR 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; S 1064, the Sun Act; S 965, the Family Act; HR 2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act.

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; HR 2941 and S 3493; HR 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S. 1064, the Sun Act; S 965, the Family Act; HR2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, and issues relating to the ongoing national shortage of cancer drugs.

Client expense: $1,030,000 · Firm income: Not reported

Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S 494 and HR 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; HR 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; HR 1217, Repeal Prevention and Public Health Fund; HR 1740 and HR 5560, the Quality Cancer Care for Life Act of 2010; HR 2941 and S 3493; HR 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S. 1064, the Sun Act; S 965, the Family Act; HR2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act.

Client expense: $1,420,000 · Firm income: Not reported

Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 494 and H.R. 912; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention & Public Health Fund; S. 488, the Access to Cancer Clinical Trials Act of 2009; H.R. 1740 and H.R. 5660, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493, Johanna's Law reauthorization; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 2366, the Cancer Drug Coverage Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; and child nutrition reauthorization bills(H.R. 5504, Improving Nutrition for America's Children Act, and S. 3307, Healthy, Hunger-Free Kids Act).

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R.1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S.494, and H.R.912; H.R.1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R.1217, Repeal Prevention & Public Health Fund; S.488, the Access to Cancer Clinical Trials Act of 2009; H.R.1740 and H.R.5560, the Quality Cancer Care for Life Act of 2010; H.R.2941 and S.3493, H.R.3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R.2366, the Cancer Drug Coverage Act of 2009; H.R.4662, The Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; the implementation of P.L.111-148, the Patient Protection and Affordable Care Act of 2010; S.1064, the Sun Act; S.965, the Family Act, and H.R.2077, the MLR Repeal Act.

Client expense: $540,000 · Firm income: Not reported

Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 494 and H.R. 912; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention & Public Health Fund; S. 488, the Access to Cancer Clinical Trials Act of 2009; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493, Johanna's Law reauthorization; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 2366, the Cancer Drug Coverage Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; the implemenatation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; and child nutrition reauthorization bills (H.R. 5504, Improving Nutrition for America's Children Act, and S. 3307, Healthy, Hunger-Free Kids Act).

Client expense: $420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 494 and H.R. 912 - "Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2011." Advocate support.

Client expense: Not reported · Firm income: $13,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation; H.R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 494 and H.R. 912; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention & Public Health Fund; S. 488, The Access to Cancer Clinical Trials Act of 2009; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493, Johanna's Law reauthorization; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 2366, the Cancer Drug Coverage Act of 2009; H.R. 4662, The Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; and child nutrition reauthorization bills (H.R. 5504, Improving Nutrition for America's Children Act, and S. 3307, Healthy, Hunger-Free Kids Act).

Client expense: $380,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R.1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S.494, and H.R.912; H.R.1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R.1217, Repeal Prevention & Public Health Fund; S.488, the Access to Cancer Clinical Trials Act of 2009; H.R.1740 and H.R.5560, the Quality Cancer Care for Life Act of 2010; H.R.2941 and S.3493, Johanna's Law reauthorization; H.R.3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R.2366, the Cancer Drug Coverage Act of 2009; H.R.4662, The Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; the implementation of P.L.111-148, the Patient Protection and Affordable Care Act of 2010; and child nutrition reauthorization bills (H.R.5504, Improving Nutrition for America's Children Act, and S.3307, Healthy, Hunger-Free Kids Act).

Client expense: $750,000 · Firm income: Not reported